Gå offline med appen Player FM !
Loqtorzi, Vabysmo, Omvoh, Vamorolone, Tibsovo, FluMist
Manage episode 407556901 series 3561458
Check out our free downloads at nascentmc.com:
- Implementing AMA Style – 8 Things to Get Right in Your Next Project
- Needs Assessments – 7 Essentials for Getting Funded
- Working With Your Medical Writer – 8 Ways to Get the Most out of Them
See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights:
· Loqtorzi (toripalimab-tpzi) has received FDA approval for the treatment of nasopharyngeal carcinoma, both in combination with chemotherapy and as a monotherapy, demonstrating significant improvements in progression-free survival and overall survival.
· Vabysmo (faricimab-svoa) has been approved by the FDA as a treatment for macular edema following retinal vein occlusion, showing early and sustained vision improvement in patients, with a generally well-tolerated safety profile.
· Omvoh (mirikizumab-mrkz) has gained FDA approval for the treatment of moderate-to-severe active ulcerative colitis, offering a targeted approach to address inflammation in this chronic inflammatory bowel disease.
· Agamree (vamorolone) oral suspension has been approved by the FDA as a novel corticosteroid treatment for Duchenne muscular dystrophy, demonstrating efficacy in improving muscle function with a favorable safety profile.
· Tibsovo (ivosidenib) has received FDA approval for adult patients with relapsed/refractory myelodysplastic syndromes carrying an IDH1 mutation, offering a potential treatment option for this specific group.
· The FDA is reviewing AstraZeneca's application to allow patients or caregivers to self-administer FluMist Quadrivalent, potentially becoming the first self-administered flu vaccine, with a decision expected in the first quarter of 2024.
Intro and outro music
60 episoder
Manage episode 407556901 series 3561458
Check out our free downloads at nascentmc.com:
- Implementing AMA Style – 8 Things to Get Right in Your Next Project
- Needs Assessments – 7 Essentials for Getting Funded
- Working With Your Medical Writer – 8 Ways to Get the Most out of Them
See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights:
· Loqtorzi (toripalimab-tpzi) has received FDA approval for the treatment of nasopharyngeal carcinoma, both in combination with chemotherapy and as a monotherapy, demonstrating significant improvements in progression-free survival and overall survival.
· Vabysmo (faricimab-svoa) has been approved by the FDA as a treatment for macular edema following retinal vein occlusion, showing early and sustained vision improvement in patients, with a generally well-tolerated safety profile.
· Omvoh (mirikizumab-mrkz) has gained FDA approval for the treatment of moderate-to-severe active ulcerative colitis, offering a targeted approach to address inflammation in this chronic inflammatory bowel disease.
· Agamree (vamorolone) oral suspension has been approved by the FDA as a novel corticosteroid treatment for Duchenne muscular dystrophy, demonstrating efficacy in improving muscle function with a favorable safety profile.
· Tibsovo (ivosidenib) has received FDA approval for adult patients with relapsed/refractory myelodysplastic syndromes carrying an IDH1 mutation, offering a potential treatment option for this specific group.
· The FDA is reviewing AstraZeneca's application to allow patients or caregivers to self-administer FluMist Quadrivalent, potentially becoming the first self-administered flu vaccine, with a decision expected in the first quarter of 2024.
Intro and outro music
60 episoder
Alle episoder
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.